Statistik Asas
| CIK | 1808865 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to iTeos Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of iTeos Therapeutics, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Section 1.2 Ot |
|
| August 29, 2025 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Sol |
|
| August 29, 2025 |
CONTINGENT VALUE RIGHTS AGREEMENT Exhibit (d)(6) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc. |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 29, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ITEOS THERAPEUTICS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. I. The name of this corporation is iTeos Therapeutics, Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered agent of th |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) T |
|
| August 29, 2025 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No.1) iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46 |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) TA |
|
| August 15, 2025 |
Exhibit (d)(1) Execution Version AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| August 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) ITEOS THERAPEUTICS, INC. |
|
| August 1, 2025 |
Exhibit (d)(3) LIMITED GUARANTY This Limited Guaranty, dated as of July 18, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of iTeos Therapeutics, Inc. |
|
| August 1, 2025 |
EX-99.(e)(12) Exhibit (e)(12) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. I. The name of this corporation is iTeos Therapeutics, Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be Corporation Service Center, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered a |
|
| August 1, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC. |
|
| August 1, 2025 |
Exhibit (d)(2) AGREEMENT FOR DISCLOSURE OF CONFIDENTIAL INFORMATION FROM ITEOS THERAPEUTICS INC. |
|
| August 1, 2025 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2025 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC. |
|
| August 1, 2025 |
Form of Letter of Transmittal (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO). Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of ITEOS THERAPEUTICS, INC. |
|
| August 1, 2025 |
Form of Amended and Restated Bylaws of the Company to be effective at the Effective Time. EX-99.(e)(13) Exhibit (e)(13) AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of iTeos Therapeutics, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Sec |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ITEOS THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror 1)) CONCENTRA MERGER SUB VIII, INC. (Name of Filing Persons (Co-Offeror 2)) TANG CAPITAL PARTNER |
|
| August 1, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ITEOS THERAPEUTICS, INC. |
|
| July 22, 2025 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Numb |
|
| July 21, 2025 |
Execution Version AGREEMENT AND PLAN OF MERGER DATED AS OF JULY 18, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VIII, INC. |
|
| July 21, 2025 |
Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•] (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), [•], as Rights Agent (as defined herein), |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 21, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Name of Subject Company) iTeos Therapeutics, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Numb |
|
| July 21, 2025 |
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10. |
|
| June 17, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 28, 2025 |
FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND MATT CALL This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and Matt Call (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of the closing o |
|
| May 28, 2025 |
FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND DAVID FELTQUATE This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and David Feltquate (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of J |
|
| May 28, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 28, 2025 |
FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT BETWEEN ITEOS THERAPEUTICS, INC. AND MICHEL DETHEUX This First Amendment (the “First Amendment”) dated this 27th day of May, 2025 is made by and between iTeos Therapeutics, Inc. (the “Company”) and Michel Detheux (the “Executive”). WHEREAS, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”) effective as of the |
|
| May 28, 2025 |
iTeos Therapeutics Announces Its Intention to Wind Down Operations - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass. |
|
| May 13, 2025 |
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival - Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program - iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 24, 2025 |
Table of Contents ev UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 5, 2025 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc. |
|
| March 5, 2025 |
Exhibit 19.1 ITEOS THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the amended and restated policy of iTeos Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (the “In |
|
| March 5, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Exhibit 10.15 David Feltquate [***] July 18, 2024 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and David Feltquate (the “Executive”) and is effective as of July 31, 2024 (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and condit |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 13, 2025 |
Advancing Science. Designing Hope. JPM HC Conference January 2025 Advancing Science. Designing Hope. JPM HC Conference January 2025 Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are in |
|
| November 21, 2024 |
ITOS / iTeos Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment SC 13G 1 sc13g07422itos11212024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title |
|
| November 21, 2024 |
EX-99.1 2 ex991to13g07422itos112124.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 21, 2024 with respect to the Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on b |
|
| November 18, 2024 |
Joint Filing Agreement, dated November 18, 2024, among Mr. Davis and BCM. CUSIP No. 46565G104 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree that |
|
| November 18, 2024 |
Joint Filing Agreement, dated November 18, 2024, among Mr. Davis and BCM. EX-4 2 ff4136206ex4-iteos.htm CUSIP No. 46565G104 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutic |
|
| November 18, 2024 |
ITOS / iTeos Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff413620613da6-iteos.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 ( |
|
| November 18, 2024 |
ITOS / iTeos Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) Josh La Grange Fried, |
|
| November 14, 2024 |
ITOS / iTeos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 itos13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ITeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 15, 2024 |
ITOS / iTeos Therapeutics, Inc. / Boxer Asset Management Inc. Activist Investment SC 13D/A 1 ff399106113da5-iteos.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 ( |
|
| October 15, 2024 |
ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff399714013da-iteosboxcap.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G |
|
| September 30, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree to the filing of |
|
| September 30, 2024 |
ITOS / iTeos Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 16, 2024 |
Cancer Immunotherapies by design™ GALAXIES Lung-201 Update ESMO 2024 Cancer Immunotherapies by design™ GALAXIES Lung-201 Update ESMO 2024 Forward-Looking Statements This presentation contains forward-looking statements. |
|
| September 16, 2024 |
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - Clinically meaningful objective response rate (ORR) of 63. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| June 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) Josh La Grange Fried, |
|
| May 14, 2024 |
ITOS / iTeos Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2414521d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA |
|
| May 13, 2024 |
EX-4.1 Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN |
|
| May 13, 2024 |
EX-4.2 Exhibit 4.2 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: May 14, 2024 iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), |
|
| May 13, 2024 |
EX-99.1 Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 10, 2024, by and among iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, including its successors and assigns, an “Investor” and together, the “Investors”). WHEREAS, the Company des |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271793 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) iTeos Therapeutics, Inc. 1,142,857 Shares of Common Stock Pre-Funded Warrant to Purchase up to 5,714,285 Shares of Common Stock We are offering directly to Boxer Capital, LLC (“Boxer Capital”) 1,142,857 shares of our common stock, par value $0.001 per share (the “ |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 6, 2024 |
iTeos Therapeutics Inc. Policy for Recoupment of Incentive Compensation Exhibit 97.1 ITEOS THERAPEUTICS, INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1. Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of iTeos Therapeutics, Inc. (the “Company”) has adopted a policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu |
|
| March 6, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware |
|
| February 16, 2024 |
ITOS / iTeos Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G 1 iteostherapeutics13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ITeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) February 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga207422itos02142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par |
|
| February 13, 2024 |
ITOS / iTeos Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01232-iteostherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: iTeos Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 46565G104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| January 10, 2024 |
Cancer Immunotherapies by design ™ Nasdaq: ITOS January 2024iteostherapeutics.com Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar ex |
|
| January 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 10, 2024 |
Cancer Immunotherapies by design™ Nasdaq: ITOS January 2024 Cancer Immunotherapies by design™ Nasdaq: ITOS January 2024 Forward-Looking Statements This presentation contains forward-looking statements. |
|
| January 9, 2024 |
ITOS / iTeos Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ITOSSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ITEOS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appro |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| October 24, 2023 |
ITOS / ITeos Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ITOSSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ITEOS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46565G104 (CUSIP Number) OCTOBER 17, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| August 8, 2023 |
Consulting Agreement between the Registrant and Detlev Biniszkiewicz effective as of June 13, 2023 Exhibit 10.1 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: June 13, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Detlev Biniszkiewicz (“You” or “Consultant”) CONSULTANT’S ADDRESS: [***] (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Consultancy Letter Agree |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| August 8, 2023 |
Consulting Agreement between the Registrant and Joanne Jenkins Lager effective as of July 21, 2023 Exhibit 10.2 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: July 21, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Dr. Joanne Jenkins Lager (“You” or “Consultant”) CONSULTANT’S ADDRESS: [***] (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Dear Dr. Lager, This |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 19, 2023 |
Table of Contents PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| May 17, 2023 |
United States Belgium 321 Arsenal Street Rue des Freres Wright Bldg 312, Suite 301 6041 Gosselies, Belgium Watertown, MA 02472-5710 May 17, 2023 VIA EDGAR U. |
|
| May 10, 2023 |
As filed with the Securities and Exchange Commission on May 10, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. |
|
| May 10, 2023 |
Sales Agreement, dated as of May 10, 2023, by and between the Registrant and Cowen and Company, LLC Exhibit 1.2 ITEOS THERAPEUTICS, INC. UP TO $125,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENT May 10, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company a |
|
| May 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) iTeos Therapeutics, Inc. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 15, 2023 |
Exhibit 10.18 Informal translation from the original French ADDENDUM TO THE EMPLOYMENT CONTRACT BETWEEN The company iTeos Belgium SA Whose registered office is located at Rue des Frères Wright 29 6041 Gosselies – Belgium Company number: 0838.316.659 here represented by Michel Detheux in his capacity as CEO and President hereinafter referred to as the “Employer” or the “Company” AND Mrs Yvonne McGr |
|
| March 15, 2023 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc. |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware |
|
| March 15, 2023 |
Exhibit 10.15 Execution Copy Amendment No. 2 to Collaboration and LICENSE AGREEMENT This Amendment No. 2 (“Amendment No. 2”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) and previously amended on January 24, 2022, between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having busin |
|
| March 15, 2023 |
Exhibit 10.14 Execution Version Amendment No. 1 to Collaboration and LICENSE AGREEMENT This Amendment No. 1 (“Amendment No. 1”) to the Collaboration and License Agreement dated June 11, 2021 (the “Agreement”) between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brent |
|
| March 15, 2023 |
image health Exhibit 10.22 CONSULTANCY LETTER AGREEMENT EFFECTIVE DATE: January 31, 2023 BY AND BETWEEN: ITEOS THERAPEUTICS INC. (“ITEOS”) ADDRESS: 321 Arsenal St., Watertown, MA 02472 AND CONSULTANT’S NAME: Matthew Roden (“You” or “Consultant”) CONSULTANT’S ADDRESS: (hereinafter ITEOS and Consultant being referred to as the “Parties” collectively or “Party” individually). RE: Consultancy Letter A |
|
| March 15, 2023 |
Exhibit 10.19 321 Arsenal Street Bldg. 312, Suite 301 Watertown, MA 02472-5710 United States Informal translation from the original French Yvonne McGrath [***] Gosselies, Belgium November 23, 2022 Dear Mrs. Yvonne McGrath, Concerns: iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan This letter concerns the potential grant and/or any given grant to Yvonne McGrath (the “Optionee”) of sto |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2023 |
ITOS / iTeos Therapeutics Inc / RTW INVESTMENTS, LP - ITEOS THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0696sc13ga.htm ITEOS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46565G104 (CUSIP Number) |
|
| February 9, 2023 |
ITOS / iTeos Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01193-iteostherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: iTeos Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 46565G104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule purs |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 9, 2023 |
Better Immunotherapies to Improve the Lives of People with Cancer Nasdaq: ITOS January 2023 Better Immunotherapies to Improve the Lives of People with Cancer Nasdaq: ITOS January 2023 Forward-Looking Statements This presentation contains forward-looking statements. |
|
| January 9, 2023 |
iteostherapeutics.com Better Immunotherapies to Improve the Lives of People with Canceriteostherapeutics.com Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential, |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| November 10, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO THE ITEOS THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN Pursuant to Section 18 of the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the ?Plan?), the Plan is hereby amended as follows: The definition of ?Compensation? in Section 11 of the Plan is hereby deleted and replaced in its entirety with the following: ?The term ?Compensation? means the am |
|
| August 12, 2022 |
iTeos Therapeutics, Inc. 321 Arsenal Street, Building 3, Suite 301 Watertown, MA 02472 www.iTeosTherapeutics.com VIA EDGAR August 12, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Li Xiao and Mary Mast Re: iTeos Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 23, 2022 File N |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| June 13, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2022 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2022 |
ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as amended (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of iTeos Therapeutics, Inc. (the ?Company?) |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| May 11, 2022 |
ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 2, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 2, 2022 with respect to the Common Stock, $0.001 par value per share of iTeos Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with th |
|
| May 2, 2022 |
ITOS / iTeos Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 23, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts iTeos BE, LLC Delaware |
|
| March 23, 2022 |
Exhibit 10.14 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 8 day of November, 2021, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ITEOS THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: The specific building in the Project located at 321 Arsenal Street, Watertown, Massachusetts 02472 (also known as Building 312), |
|
| March 23, 2022 |
Exhibit 10.15 Translated from the original French EMPLOYMENT CONTRACT BETWEEN The company iTeos Belgium SA Having its registered address at Rue des Freres Wright 29 3041 Gosselies ? Belgium Company number: 0838.316.659 Represented by Philippe Brantegem In his capacity as Vice-President Human Resources Hereafter referred to as ? the Employer ? or ? the Company ? AND Mrs. Yvonne McGrath Residing at |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu |
|
| March 23, 2022 |
As filed with the Securities and Exchange Commission on March 23, 2022 As filed with the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) iTeos Therapeutics, Inc. |
|
| March 21, 2022 |
ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ITOS / iTeos Therapeutics Inc / RTW INVESTMENTS, LP - ITEOS THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu |
|
| January 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 11, 2022 |
Targeted Immunotherapies to Improve the Lives of People with Cancer January 2022 Nasdaq: ITOS Targeted Immunotherapies to Improve the Lives of People with Cancer January 2022 Nasdaq: ITOS Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. |
|
| January 6, 2022 |
ITOS / iTeos Therapeutics Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 10, 2021 |
ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person |
|
| December 10, 2021 |
Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| October 19, 2021 |
Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. |
|
| October 19, 2021 |
ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person |
|
| September 21, 2021 |
Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. |
|
| September 21, 2021 |
ITOS / iTeos Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person |
|
| August 11, 2021 |
Exhibit 10.1** Certain information (indicated by ?[***]?) and schedules have been excluded from this agreement because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT Between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED And ITEOS belgium s.a. Table of Contents Article 1 Definitions 1 Article 2 Effectiv |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission |
|
| June 14, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 iTeos Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDED AND RESTATED COLLABORATION AGREEMENT This Third Amended and Restated Collaboration Agreement (the ?Agreement?) is |
|
| May 13, 2021 |
iTeos Reports First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports First Quarter 2021 Financial Results and Provides Business Update - Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 - - Inupadenant updated monotherapy clinical data and evidence of association of A2A receptor expression with anti-tumor act |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commission F |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 (April 29, 2021) ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporatio |
|
| May 4, 2021 |
Exhibit 99.1 iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors Cambridge, MA and Gosselies, Belgium ? May 3, 2021 ? iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for pat |
|
| April 12, 2021 |
Exhibit 99.1 iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 ? Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed ? EOS-448 showed prelimina |
|
| April 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 (April 10, 2021) ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorpora |
|
| April 12, 2021 |
Immunotherapies to Improve and Extend the Lives of People with Cancer EOS-448 update - April 12th, 2021 Exhibit 99. |
|
| March 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 24, 2021 |
As filed with the Securities and Exchange Commission on March 24, 2021 Registration No. |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeu |
|
| March 24, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium iTeos Securities Corporation Massachusetts |
|
| March 24, 2021 |
Exhibit 4.3 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The common stock, par value $0.001 per share (?Common Stock?), of iTeos Therapeutics, Inc. (?iTeos,? ?we,? or ?our?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description sets forth certain general terms and p |
|
| March 24, 2021 |
iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12th to discuss results – - Updated, single-agent data of inupadenant (EOS-850) from Phase 1/2a trial and initial pe |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 4, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of iTeos Therapeutics, Inc. |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 11, 2021 |
EX-99.1 Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021 Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Lit |
|
| January 11, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Comm |
|
| November 12, 2020 |
iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update - Patient enrollment in Phase 1/2 studies of EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continues with initial data expected in 1H21 - - Strong cash position to support ongoing clinical development and operations into 2023 - Cambridge, MA and Gosselies, Belgium – November 12, 2020 |
|
| November 12, 2020 |
iTeos Appoints Matthew Roden, Ph.D. to Board of Directors Exhibit 99.2 iTeos Appoints Matthew Roden, Ph.D. to Board of Directors Cambridge, MA and Gosselies, Belgium – November 12, 2020 - iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Matthew Roden, Ph.D., |
|
| November 12, 2020 |
Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression November 2020 Exhibit 99. |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| September 1, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 ITEOS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39401 84-3365066 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 1, 2020 |
iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update - July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 - - EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continue to progress in clinical trials- Cambridge, MA and Gosselies, Belgium – September 1, 2020 - iTeos Therapeutics, Inc. (Nasdaq: ITOS), a |
|
| September 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39401 iTeos Therapeutics, Inc. |
|
| August 10, 2020 |
ITOS / iTeos Therapeutics, Inc. / MPM BioVentures 2014, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46565G104 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of P |
|
| August 10, 2020 |
EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. is filed on behalf of each of the undersigned. Date: August 7, 2020 MPM BIOVENTURES 2014, L.P. By: MPM BioVentures 2014 GP LLC, its General Pa |
|
| August 7, 2020 |
ITOS / iTeos Therapeutics, Inc. / Boxer Capital, LLC - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 7, 2020 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree that this Joint Filing Agreement |
|
| August 5, 2020 |
ITOS / iTeos Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* iTeos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46565G104 (CUSIP Number) RA Ca |
|
| July 28, 2020 |
EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla |
|
| July 28, 2020 |
EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. iTeos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is iTeos Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secreta |
|
| July 28, 2020 |
S-8 As filed with the Securities and Exchange Commission on July 28, 2020 Registration No. |
|
| July 28, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 ITEOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39401 84-3365066 (State or other jurisdiction of incorporation) (Commiss |
|
| July 27, 2020 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-239415 PROSPECTUS 10,586,316 Shares Common stock This is an initial public offering of shares of common stock by iTeos Therapeutics, Inc. We are offering 10,586,316 shares of our common stock. The initial public offering price is $19.00 per share. Prior to this offering, there has been no public market for our shares. Ou |
|
| July 23, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on July 23, 2020. Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 84-3365066 (State or other jurisdiction of incorporation or organizat |
|
| July 21, 2020 |
CORRESP July 21, 2020 United States Securities and Exchange Commission 100 F Street, N. |
|
| July 21, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 iTeos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3365066 (State of incorporation or organization) (I.R.S. Employer Identification No.) 139 Main Str |
|
| July 21, 2020 |
CORRESP VIA EDGAR July 21, 2020 Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| July 20, 2020 |
Form of Director Indemnification Agreement EX-10.8 Exhibit 10.8 ITEOS THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve th |
|
| July 20, 2020 |
EX-10.12 Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Matthew Gall (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Da |
|
| July 20, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ITEOS THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla |
|
| July 20, 2020 |
CORRESP July 20, 2020 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| July 20, 2020 |
EX-10.10 Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Matt Call (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date” |
|
| July 20, 2020 |
EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Michel Detheux (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Da |
|
| July 20, 2020 |
EX-10.4 Exhibit 10.4 CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. BIOLOGICS MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is dated March 22, 2 |
|
| July 20, 2020 |
EX-10.7 Exhibit 10.7 ITEOS THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the |
|
| July 20, 2020 |
EX-4.2 Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.001 Certificate Shares Number * * 000000 ****************** * * * 000000 ***************** ZQ00000000 **** 000000 **************** ITEOS THERAPEUTICS, INC. ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David |
|
| July 20, 2020 |
S-1/A Table of Contents As filed with Securities and Exchange Commission on July 20, 2020 Registration No. |
|
| July 20, 2020 |
EX-10.5 Exhibit 10.5 ITEOS THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of iTeos Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share ( |
|
| July 20, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 J.P. MORGAN SECURITIES LLC ITEOS THERAPEUTICS, INC. [•] Shares of Common Stock Underwriting Agreement July [●], 2020 J.P. Morgan Securities LLC SVB Leerink LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC One Federal Street, 37th Floor |
|
| July 20, 2020 |
EX-10.2 Exhibit 10.2 ITEOS THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of iTeos Therapeutics, Inc. (the “Company”) an |
|
| July 20, 2020 |
Form of Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement EX-10.13 Exhibit 10.13 Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement In consideration and as a condition of my employment by between iTeos Therapeutics, Inc. (including its subsidiaries and other affiliates and its and their successors and assigns, the “Company”) and in exchange for, among other things, my eligibility for certain severance benefits provided in |
|
| July 20, 2020 |
EX-10.11 Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between iTeos Therapeutics, Inc. (the “Company”), and Joanne Jenkins Lager, (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Eff |
|
| July 20, 2020 |
Senior Executive Cash Incentive Bonus Plan EX-10.6 Exhibit 10.6 ITEOS THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of iTeos Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals an |
|
| July 20, 2020 |
EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. iTeos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is iTeos Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secreta |
|
| June 24, 2020 |
EX-10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT THIS SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agre |
|
| June 24, 2020 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ITEOS THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law). DOES HEREBY CERTIFY: 1. |
|
| June 24, 2020 |
EX-10.1 Exhibit 10.1 ITEOS THERAPEUTICS, INC. 2019 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the iTeos Therapeutics, Inc. 2019 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of iTeos Therapeutics, Inc., a Delaware corporat |
|
| June 24, 2020 |
EX-4.1 Exhibit 4.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT THIS AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”), is mad |
|
| June 24, 2020 |
S-1 Table of Contents As filed with Securities and Exchange Commission on June 24, 2020 Registration No. |
|
| June 24, 2020 |
By-laws of the Registrant, as currently in effect EX-3.3 Exhibit 3.3 BY-LAWS of ITEOS THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors; provided, however, that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held |
|
| June 24, 2020 |
CORRESP June 24, 2020 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| June 24, 2020 |
Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization iTeos Therapeutics S.A. Belgium |
|
| May 22, 2020 |
BY-LAWS ITEOS THERAPEUTICS, INC. (the “Corporation”) EX-3.3 Exhibit 3.3 BY-LAWS of ITEOS THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors; provided, however, that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held |
|
| May 22, 2020 |
DRS Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on May 22, 2020. |
|
| May 22, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITEOS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ITEOS THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law). DOES HEREBY CERTIFY: 1. |
